Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

The oral AntibioticS approprIateness score (OASIS) - A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)

Christopher Orchard, Shelley Srivastava, Julianna Burgess, Nicholas Simmonds, Diana Bilton, Emma H. Baker
European Respiratory Journal 2013 42: P1178; DOI:
Christopher Orchard
1Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
2National Heart Lung Institute, Imperial College, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shelley Srivastava
1Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
3Centre for Clinical Pharmacology, St George's, University of London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julianna Burgess
2National Heart Lung Institute, Imperial College, London, United Kingdom
1Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Simmonds
1Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
2National Heart Lung Institute, Imperial College, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diana Bilton
1Department of Cystic Fibrosis, Royal Brompton Hospital, London, United Kingdom
2National Heart Lung Institute, Imperial College, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emma H. Baker
3Centre for Clinical Pharmacology, St George's, University of London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Objectives: Prompt antibiotic treatment for CF pulmonary exacerbations probably preserves lung function and prolongs survival. Oral administration is common, but choice can be determined by resource and social factors as well as clinical need. We developed an objective score to support appropriate oral antibiotic choice in CF.

Methods: Adult CF patients underwent baseline assessment and follow up for 1 year. Clinical factors associated with choice of antibiotic route for first exacerbation were identified by logistic regression and comprised the Oral AntibioticS ApproprIateness Score (OASIS). The relationship between OASIS, treatment choice and exacerbation rate was determined.

Results: Of 254 patients (31±9yrs), 198 (78%) had >1 exacerbation. Factors associated with intravenous antibiotics for first exacerbation were baseline FEV1 <47% predicted, IV antibiotics in previous year, chest symptoms, Ps. aeruginosa/ gram –ve bacteria on sputum culture. OASIS allocates 1 point per factor, range 0 (good) to 4 (bad). Patients with lower OASIS had less annual exacerbations (0, 2.2; 1, 2.7; 2, 2.9; 4, 3.5; 4, 4.4, p<0.001) and were less likely to re-exacerbate following a course of oral antibiotics (p=0.02)

View this table:
  • View inline
  • View popup

Conclusion: OASIS identifies patients with exacerbations more likely to respond to oral antibiotics. This use is currently undergoing further validation.

  • Cystic fibrosis
  • Exacerbation
  • Treatments
  • © 2013 ERS
Previous
Back to top
Vol 42 Issue Suppl 57 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The oral AntibioticS approprIateness score (OASIS) - A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The oral AntibioticS approprIateness score (OASIS) - A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)
Christopher Orchard, Shelley Srivastava, Julianna Burgess, Nicholas Simmonds, Diana Bilton, Emma H. Baker
European Respiratory Journal Sep 2013, 42 (Suppl 57) P1178;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The oral AntibioticS approprIateness score (OASIS) - A novel scoring system to assess antibiotic route in pulmonary exacerbations of cystic fibrosis (CF)
Christopher Orchard, Shelley Srivastava, Julianna Burgess, Nicholas Simmonds, Diana Bilton, Emma H. Baker
European Respiratory Journal Sep 2013, 42 (Suppl 57) P1178;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Could nan1-expression and production by pseudomonas aeruginosa be a prognostic factor for survival in CF patients
  • Ability of the lung clearance index to monitor progression of early lung disease in children with cystic fibrosis
  • Comparison of bronchodilator responsiveness in children with primary ciliary dyskinesia and cystic fibrosis
Show more 7.3 Cystic Fibrosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society